This advocates that chemotherapy/G-CSF mobilization with vinorelbine/G-CSF for patients without pre-existing polyneuropathy or with gemcitabine/G-CSF for patients with pre-existing polyneuropathy should remain standard of care. Here, CSF3 is linked to polyneuropathy.